MX2009006233A - Ion channel modulators. - Google Patents

Ion channel modulators.

Info

Publication number
MX2009006233A
MX2009006233A MX2009006233A MX2009006233A MX2009006233A MX 2009006233 A MX2009006233 A MX 2009006233A MX 2009006233 A MX2009006233 A MX 2009006233A MX 2009006233 A MX2009006233 A MX 2009006233A MX 2009006233 A MX2009006233 A MX 2009006233A
Authority
MX
Mexico
Prior art keywords
sup
compounds
hydrates
esters
pharmaceutically acceptable
Prior art date
Application number
MX2009006233A
Other languages
Spanish (es)
Inventor
Andrew Fensome
Jeffrey Curtis Kern
Hormoz Mazdiyasni
William Jay Moore
Robert Zelle
Vincent P Galullo
Paul Will
Christopher Todd Baker
Jinsong Guo
Edward George Melenski
Justin Kaplan
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of MX2009006233A publication Critical patent/MX2009006233A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

The present teachings provide compounds of Formula (I) and pharmaceutically acceptable salts, hydrates, and esters thereof, wherein Ar, R<sup>1</sup>, R<sup>1'</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup> R<sup>4'</sup>, and p are defined herein. The present teachings also provide processes for producing said compounds and their pharmaceutically acceptable salts, hydrates and esters, and methods of treating a pathological condition or disorder, or alleviating a symptom thereof, using said compounds including their pharmaceutically acceptable salts, hydrates and esters. The compounds can be useful in modulating ion channel activity including treating a variety of conditions associated with the abnormal modulation of one or more voltage-gated calcium channels.
MX2009006233A 2006-12-11 2007-12-11 Ion channel modulators. MX2009006233A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87417806P 2006-12-11 2006-12-11
PCT/US2007/087073 WO2008073934A1 (en) 2006-12-11 2007-12-11 Ion channel modulators

Publications (1)

Publication Number Publication Date
MX2009006233A true MX2009006233A (en) 2009-06-22

Family

ID=39232951

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009006233A MX2009006233A (en) 2006-12-11 2007-12-11 Ion channel modulators.

Country Status (5)

Country Link
EP (1) EP2091917A1 (en)
JP (1) JP2010512417A (en)
CA (1) CA2672236A1 (en)
MX (1) MX2009006233A (en)
WO (1) WO2008073934A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010013192A (en) * 2008-06-16 2010-12-17 Hoffmann La Roche Heteroaromatic monoamides as orexinin receptor antagonists.
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US9783490B2 (en) * 2012-12-18 2017-10-10 The Secretary Of State For Health Antimicrobial compounds, their synthesis and applications thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601363B1 (en) * 1986-07-08 1988-10-21 Synthelabo (DIMETHYLAMINO) -2 ETHYL) (((((METHYLTHIO) -2 PHENYL) (PHENYLMETHYL) AMINO) -2 OXO-2 ETHYL) CARBAMATES OR UREA, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION.
US7125848B2 (en) * 2003-06-13 2006-10-24 Dynogen Pharmaceuticals, Inc. Methods of treating non-inflammatory gastrointestinal tract disorders using Cav2.2 subunit calcium channel modulators

Also Published As

Publication number Publication date
CA2672236A1 (en) 2008-06-19
WO2008073934A1 (en) 2008-06-19
JP2010512417A (en) 2010-04-22
EP2091917A1 (en) 2009-08-26

Similar Documents

Publication Publication Date Title
MX2009006234A (en) Ion channel modulators.
MX2009006232A (en) Carboxamide derivatives as ion channel modulators.
WO2008073461A3 (en) Ion channel modulators
WO2007146165A3 (en) Bone plates with intraoperatively tapped apertures
SG159474A1 (en) Conjugated diene polymer, conjugated diene polymer composition, and method for producing conjugated diene polymer
NZ590495A (en) Dihydropyridin-phenyl-3-oxazinan-2-ones as inhibitors of 11beta-hydroxysteroid dehydrogenase 1
GB2453819A (en) Modulators of hypoxia inducible factor-1 and related uses
WO2007115409A8 (en) Compositions and methods for modulating gated ion channels
PH12014502584A1 (en) Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
WO2004112587A3 (en) Bone plates with intraoperatively tapped apertures
NO20065768L (en) Karbonsamid-opioidforbindelser
TNSN08406A1 (en) 6-o-substituted benzoxazole and benzothiazole compounds and methods of inhibiting csf-1r signaling
MY144622A (en) Agents for preventing and treating disorders involving modulation of the ryr receptors
PT2368550E (en) Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
WO2007092190A3 (en) Methods and compositions for modulating sphingosine-1-phosphate (s1p) receptor activity
WO2010017122A3 (en) Methods of treating thalassemia
AU2003240517A1 (en) Substituted pyrrolines as kinase inhibitors
WO2008028141A3 (en) Raf inhibitor compounds and methods of use thereof
SG162671A1 (en) New process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
WO2008060626A3 (en) Compounds for modulating trpv3 function
MX2009008288A (en) Compounds that inhibit cholinesterase.
WO2004106296A3 (en) Trisubstituted heteroaromatic compounds as calcium sensing receptor modulators
MX2009006233A (en) Ion channel modulators.
WO2007011702A3 (en) Use of egfr inhibitors to prevent or treat obesity
WO2006116773A3 (en) Methods, compositions, and compounds for modulation of monoacylglycerol lipase, pain, and stress-related disorders

Legal Events

Date Code Title Description
HH Correction or change in general
FA Abandonment or withdrawal